ArticleThe EPMA journal2010
Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy.
Article in The EPMA journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Is Alzheimer disease a disease?Nature reviews. Neurology · 2024Review
- Rise of Deep Learning Clinical Applications and Challenges in Omics Data: A Systematic Review.Diagnostics (Basel, Switzerland) · 2023Review
- Salivary Biomarkers: Noninvasive Ways for Diagnosis of Parkinson's Disease.Neurology research international · 2023Review
- Evolutionary and genomic perspectives of brain aging and neurodegenerative diseases.Progress in brain research · 2023Article
- Synergic control in asymptomatic welders during multi-finger force exertion and load releasing while standing.Neurotoxicology · 2022Article
- Traumatic brain injury and the development of parkinsonism: Understanding pathophysiology, animal models, and therapeutic targets.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases.The EPMA journal · 2017Review
- Can Biomarkers Help the Early Diagnosis of Parkinson's Disease?Neuroscience bulletin · 2017Review
- Synergy as a new and sensitive marker of basal ganglia dysfunction: A study of asymptomatic welders.Neurotoxicology · 2016Article
- Current status of biomarker research in neurology.The EPMA journal · 2016Review
- EPMA summit 2014 under the auspices of the presidency of Italy in the EU: professional statements.The EPMA journal · 2015Article
- Neurodegeneration: accelerated ageing or inadequate healthcare?The EPMA journal · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases like Parkinson's disease (PD) and Alzheimer's disease (AD) are considered disorders of multifactorial origin, inevitably progressive and having a long preclinical period. Therefore, the availability of biological markers or biomarkers (BMs) for early disease diagnosis will impact the management of AD and PD in several dimensions; it will 1) help to capture high-risk individuals before symptoms develop, a stage where prevention efforts might be expected to have their greatest impact; 2) provide a measure of disease progression that can be evaluated objectively, while clinical measures are much less accurate; 3) help to discriminate between true AD or PD and other causes of a similar clinical syndrome; 4) delineate pathophysiological processes responsible for the disease; 5) determine the clinical efficacy of novel, disease-modifying (neuroprotective) strategies. In the long run the availability of reliable BMs will significantly advance the research and therapeutics of AD and PD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.